ATP assay-guided chemosensitivity testing for gemcitabine with biopsy specimens obtained from unresectable pancreatic cancer using endoscopic ultrasonography-guided fine-needle aspiration

International Journal of Clinical Oncology

Volumn 16, Issue 4, 2011, Pages 387-394

  Wakatsuki, Takeru ^a,c   Irisawa, Atsushi ^a   Terashima, Masanori ^b   Shibukawa, Goro ^a   Takagi, Tadayuki ^a   Imamura, Hidemichi ^a   Takahashi, Yuta ^a   Sato, Ai ^a   Sato, Masaki ^a   Ikeda, Tsunehiko ^a   Suzuki, Rei ^a   Hikichi, Takuto ^a   Obara, Katsutoshi ^a   Ohira, Hiromasa ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b SHIZUOKA CANCER CENTER   (Japan)

^c Fukushima Red Cross Hospital   (Japan)

Author keywords

ATP assay; Chemosensitivity testing; EUS FNA; Gemcitabine; Pancreatic cancer

Indexed keywords

ADENOSINE TRIPHOSPHATE; GEMCITABINE; MIDAZOLAM;

ADULT; AGED; ANALYTICAL PARAMETERS; AREA UNDER THE CURVE; ARTICLE; ASPIRATION BIOPSY; BLOOD TOXICITY; CELL VIABILITY; CHEMOSENSITIVITY; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPUTER ASSISTED RADIOGRAPHY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG SCREENING; ENDOSCOPIC ECHOGRAPHY; ENZYME ASSAY; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS BIOPSY; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; TREATMENT RESPONSE;

ADENOSINE TRIPHOSPHATE; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BIOPSY, FINE-NEEDLE; CELL SURVIVAL; CELLS, CULTURED; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; ENDOSONOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 80052723825     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0197-3     Document Type: Article

References (37)

1. D Li K Xie R Wolff, et al. 2004 Pancreatic cancer Lancet 363 1049 1057 15051286 10.1016/S0140-6736(04)15841-8 1:CAS:528:DC%2BD2cXisFOmsLY%3D (Pubitemid 38410779)
2. HA Burris 3rd MJ Moore J Andersen, et al. 1997 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403 2413 9196156 1:CAS:528:DyaK2sXlsFKksLY%3D (Pubitemid 27251144)
3. H Yamaue H Tanimura K Noguchi, et al. 1992 Chemosensitivity testing of fresh human gastric cancer with highly purified tumour cells using the MTT assay Br J Cancer 66 794 799 1419622 10.1038/bjc.1992.362 1:STN:280: DyaK3s%2FktFShsw%3D%3D
4. H Kawamura K Ikeda I Takiyama, et al. 1997 The usefulness of the ATP assay with serum-free culture for chemosensitivity testing of gastrointestinal cancer Eur J Cancer 33 960 966 9291821 10.1016/S0959-8049(97)00075-0 1:CAS:528:DyaK2sXks1SrtLk%3D (Pubitemid 27287051)
5. Y Fujita M Hiramatsu M Kawai, et al. 2009 Histoculture drug response assay predicts the postoperative prognosis of patients with esophageal cancer Oncol Rep 21 499 505 19148528 1:CAS:528:DC%2BD1MXit1Grt7o%3D
6. K Noguchi M Iwahashi M Tani, et al. 2005 Evaluation of chemosensitivity testing with highly purified tumor cells in 435 patients with gastric carcinoma using an MTT assay Anticancer Res 25 931 937 15868930 1:CAS:528: DC%2BD2MXkt1GgtL0%3D (Pubitemid 40546865)
7. YW Moon SH Choi YT Kim, et al. 2007 Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer Cancer 109 1829 1835 17366594 10.1002/cncr.22601 1:CAS:528:DC%2BD2sXlsF2nurk%3D (Pubitemid 46668547)
8. G Konecny C Crohns M Pegram, et al. 2000 Correlation of drug response with the ATP tumor chemosensitivity assay in primary FIGO stage III ovarian cancer Gynecol Oncol 77 258 263 10785475 10.1006/gyno.2000.5728 1:CAS:528:DC%2BD3cXislCntL8%3D (Pubitemid 30317146)
9. HA Kim CK Yom BI Moon, et al. 2008 The use of an in vitro adenosine triphosphate-based chemotherapy response assay to predict chemotherapeutic response in breast cancer Breast 17 19 26 17659874 10.1016/j.breast.2007.06.001 (Pubitemid 351242569)
10. S Ugurel D Schadendorf C Pföhler, et al. 2006 In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the dermatologic cooperative oncology group Clin Cancer Res 15 5454 5463 10.1158/1078-0432.CCR-05-2763 (Pubitemid 44497261)
11. T Kondo T Kubota T Tanimura, et al. 2000 Cumulative results of chemosensitivity test for antitumor agents in Japan. Japan Research Society for Appropriate Cancer Chemotherapy Anticancer Res 20 2389 2392 10953301 1:STN:280:DC%2BD3cvhs1KrsQ%3D%3D (Pubitemid 30614442)
12. H Yasuda T Takada K Wada, et al. 1998 A new in vitro drug sensitivity test (collagen-gel droplet embedded-culture drug sensitivity test) in carcinomas of pancreas and biliary tract: possible clinical utility J Hepatobiliary Pancreat Surg 5 261 268 9880773 10.1007/s005340050044 1:STN:280: DyaK1M%2FpvFaitA%3D%3D (Pubitemid 128662591)
13. T Wakatsuki A Irisawa MS Bhutani, et al. 2005 Comparative study of diagnostic value of cytologic sampling by endoscopic ultrasonography-guided fine-needle aspiration and that by endoscopic retrograde pancreatography for the management of pancreatic mass without biliary stricture J Gastroenterol Hepatol 20 1707 1711 16246190 10.1111/j.1440-1746.2005.03900.x (Pubitemid 43961077)
14. PE Andreotti IA Cree CM Kurbacher, et al. 1995 Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma Cancer Res 55 5276 5282 7585588 1:CAS:528:DyaK2MXpsVaru7c%3D
15. K Abe T Wakatsuki F Katsushima, et al. 2009 A case of advanced intrahepatic cholangiocarcinoma successfully treated with chemosensitivity test-guided systemic chemotherapy World J Gastroenterol 64 235 241
16. T Wakatsuki A Irisawa H Imamura, et al. 2010 Complete response of anaplastic carcinoma of the pancreas to paclitaxel treatment selected by chemosensitivity testing: case report Int J Clin Oncol 15 310 313 20195681 10.1007/s10147-010-0038-9
17. C Sezgin B Karabulut R Uslu, et al. 2005 Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors Scand J Gastroenterol 40 1486 1492 16293561 10.1080/00365520510023819 1:CAS:528:DC%2BD2MXht1agt7jL (Pubitemid 43028211)
18. A Irisawa T Hikichi MS Bhutani, et al. 2009 Basic technique of FNA Gastrointest Endosc 69 Suppl 2 S125 S129 19179136 10.1016/j.gie.2008.12.017
19. E Sugiyama N Kaniwa SR Kim, et al. 2007 Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism J Clin Oncol 25 32 42 17194903 10.1200/JCO.2006.06.7405 1:CAS:528: DC%2BD2sXht1ejs78%3D (Pubitemid 350003048)
20. L Kangas M Gronroos AL Nieminen 1984 Bioluminescence of cellular ATP: a new method for evaluation cytotoxic agents in vitro Med Biol 62 338 343 6543460 1:CAS:528:DyaL2MXltFGmsbw%3D (Pubitemid 15117242)
21. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
22. WJ Youden 1950 Index for rating diagnostic tests Cancer 3 32 35 15405679 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3 1:STN:280:DyaG3c%2FhsFeisw%3D%3D
23. Y Takamura H Kobayashi T Taguchi, et al. 2002 Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers Int J Cancer 98 450 455 11920599 10.1002/ijc.10208 1:CAS:528:DC%2BD38XitVWisr0%3D (Pubitemid 34188690)
24. FA Shepherd J Dancey R Ramlau, et al. 2000 Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2095 2103 10811675 1:CAS:528:DC%2BD3cXktVyjsLc%3D (Pubitemid 30324363)
25. AF Sobrero J Maurel L Fehrenbacher, et al. 2008 EPIC; phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer J Clin Oncol 26 2311 2319 18390971 10.1200/JCO.2007.13.1193 1:CAS:528:DC%2BD1cXntVOltrk%3D
26. S Lee SY Oh BG Kim, et al. 2009 Second line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (Conti-Fam) in gemcitabine-pretreated pancreatic and biliary tract cancer Am J Clin Oncol 32 348 352 19363436 10.1097/COC.0b013e31818c08ff 1:CAS:528:DC%2BD1MXptl2hsbY%3D
27. C Morizane T Okusaka J Furuse, et al. 2009 A phase II study of S-1 in gemcitabine-refractory metaplastic pancreatic cancer Cancer Chemother Pharmacol 63 313 319 18398614 10.1007/s00280-008-0741-7 1:CAS:528:DC%2BD1cXhsVelurbN
28. T Itoi A Sofuni N Fukushima, et al. 2007 Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsy obtained from unresectable pancreatic carcinomas J Gastroenterol 42 389 394 17530364 10.1007/s00535-007-2017-0 1:CAS:528:DC%2BD2sXlslOgs7Y%3D (Pubitemid 47097256)
29. S Mori-Iwamoto Y Kuramitsu S Ryozawa, et al. 2007 Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cell to gemcitabine Int J Oncol 31 1345 1350 17982661 1:CAS:528:DC%2BD2sXhsVKgtbbP
30. P Rougier A Adenis M Ducreux, et al. 2000 A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma Eur J Cancer 36 1016 1025 10885606 10.1016/S0959-8049(00)00072-1 1:CAS:528:DC%2BD3cXjsVCqsLY%3D (Pubitemid 30316427)
31. H Ueno T Okusaka M Ikeda, et al. 2005 An early phase II study of S-1 in patients with metastatic pancreatic cancer Oncology 68 171 178 16006754 10.1159/000086771 1:CAS:528:DC%2BD2MXntFSnur8%3D (Pubitemid 41158973)
32. K Nakamura T Yamaguchi T Ishihara, et al. 2006 Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer Br J Cancer 94 1575 1579 16721372 1:CAS:528:DC%2BD28XltVOmurs%3D (Pubitemid 43924916)
33. D Cunningham I Chau DD Stocken, et al. 2009 Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer J Clin Oncol 27 5487 5491 10.1200/JCO.2009.24.2446
34. AH Ko J Hwang AP Venook, et al. 2005 Serum CA 19-9 response as a surrogate for clinical outcome receiving fixed-dose rate gemcitabine for advanced pancreatic cancer Br J Cancer 93 195 199 15999098 10.1038/sj.bjc. 6602687 1:CAS:528:DC%2BD2MXmt1yhurs%3D (Pubitemid 41133205)
35. U Halm T Schumann I Schiefke, et al. 2000 Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer Br J Cancer 82 1013 1016 10737382 10.1054/bjoc.1999.1035 1:CAS:528:DC%2BD3cXitVClsr0%3D (Pubitemid 30128852)
36. C Tibaldi E Giovannetti E Vasile, et al. 2008 Correlation of CDA, ERCC1, and XPD polymorphism with response and survival in gemcitabine/cisplatin-Treated advanced non-small cell lung cancer patients Clin Cancer Res 14 1797 1803 18347182 10.1158/1078-0432.CCR-07-1364 1:CAS:528:DC%2BD1cXjtleju78%3D (Pubitemid 351469466)
37. T Okazaki M Javle M Tanaka, et al. 2010 Single nucleotide polymorphisms of gemcitabine metabolic gene and pancreatic cancer survival and drug toxicity Clin Cancer Res 16 320 329 20028759 10.1158/1078-0432.CCR-09-1555 1:CAS:528:DC%2BC3cXot1Sm